ClinicalTrials.gg
CompletedNCT01850602Updated Oct 9, 2018Results posted

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

A Phase 3 interventional study of PA21 and Sevelamer hydrochloride in Hemodialysis and Hyperphosphatemia, sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2018-10-09.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
213
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 41 studies in Hyperphosphatemia with a site in Japan — 3 open to participants now, 4 under way, 4 of them phase 3. Hyperphosphatemia · Japan.

Enrollment
6th of 36
213 · median 117
Started
2013
with 5 others
Phase 3
23 of 41
3 open now
Registered
21st of 41
by date
Lead sponsor
5 of 41
Kissei Pharmaceutical Co., Ltd.

Among the 41 studies in Hyperphosphatemia with a site in Japan, this one is the 6th largest by enrollment of the 36 interventional ones that give a count, is one of 6 that started in 2013, is one of 23 in phase 3, and was the 21st registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

3 of the 41 studies in Hyperphosphatemia with a site in Japan are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Hyperphosphatemia with a site in Japan, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of PA21 in hemodialysis patients with hyperphosphatemia

03

Conditions studied

  • Hemodialysis
  • Hyperphosphatemia

Browse trials for

Keywords

  • Hemodialysis
  • Hyperphosphatemia
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients age 20 or older, regardless of gender.
  • Receiving stable maintenance hemodialysis 3 times a week.
  • Patients not having changed their phosphate binder agent dose, for 4 weeks or more before their observation period start.

Exclusion criteria

Exclusion Criteria:

  • Patients having history of a pronounced brain / cardiovascular disorder.
  • Patients having severe gastrointestinal disorders.
  • Patients having severe hepatic disorders.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
213 participants (actual)

Study arms

  • Experimental
    PA21

    Drug: PA21

  • Active comparator
    Sevelamer hydrochloride

    Drug: Sevelamer hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment

    Covariate: Serum phosphorus concentrations at baseline.

    Time frame: 12 weeks

Secondary outcomes

  1. Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  2. Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

  3. Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)

    Time frame: 12 weeks

07

Results

Posted Oct 9, 2018

Participant flow

Participant flow — Overall Study
MilestonePA21Sevelamer Hydrochloride
Started108105
Completed9487
Not completed1418
Withdrew: Adverse event710
Withdrew: Physician decision21
Withdrew: Withdrawal by subject24
Withdrew: Decrease in serum calcium23
Withdrew: Increase in serum ferritin10

Outcome measures

PrimaryAdjusted Mean of Serum Phosphorus Concentrations at the End of Treatment

Covariate: Serum phosphorus concentrations at baseline.

Time frame:
12 weeks
Reported as:
Mean · mg/dL
Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment
mg/dLPA21Sevelamer Hydrochloride
Adjusted Mean of Serum Phosphorus Concentrations at the End of Treatment5.00 (4.80 to 5.19)5.34 (5.13 to 5.55)
Statistical analysis
  • PA21 vs Sevelamer Hydrochloride · ANCOVA · p = 0.020 · Mean difference (final values): -0.34 · 95% CI -0.63 to -0.05
SecondarySerum Phosphorus Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · mg/dL
Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)
mg/dLPA21Sevelamer Hydrochloride
Serum Phosphorus Concentrations at End of Treatment (Actual Measured Value)5.01 ± 1.015.33 ± 1.03
SecondaryCorrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · mg/dL
Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)
mg/dLPA21Sevelamer Hydrochloride
Corrected Serum Calcium Concentrations at End of Treatment (Actual Measured Value)9.14 ± 0.688.91 ± 0.71
SecondarySerum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)
Time frame:
12 weeks
Reported as:
Mean · pg/mL
Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)
pg/mLPA21Sevelamer Hydrochloride
Serum Intact-PTH Concentrations at End of Treatment (Actual Measured Value)203.6 ± 117.1253.1 ± 168.6

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PA210/108 (0%)6/108 (5.6%)47/108 (43.5%)
Sevelamer Hydrochloride0/105 (0%)5/105 (4.8%)42/105 (40%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPA21Sevelamer Hydrochloride
DiverticulitisInfections and infestations0/1081/105
Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1081/105
Cerebral infarctionNervous system disorders0/1081/105
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders0/1081/105
Shunt stenosisInjury, poisoning and procedural complications0/1081/105
PneumoniaInfections and infestations1/1080/105
Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1080/105
Cardiac failure congestiveCardiac disorders1/1080/105
Supraventricular tachycardiaCardiac disorders1/1080/105
Acute pulmonary oedemaRespiratory, thoracic and mediastinal disorders1/1080/105
Most frequent other events
Most frequent other events
EventPA21Sevelamer Hydrochloride
DiarrhoeaGastrointestinal disorders27/1083/105
NasopharyngitisInfections and infestations24/10824/105
ConstipationGastrointestinal disorders2/10819/105

Baseline characteristics

Per Protocol Set

Age, Continuous
Age, Continuous(years)PA21Sevelamer HydrochlorideTotal
Mean61.0 ± 11.760.8 ± 12.060.9 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)PA21Sevelamer HydrochlorideTotal
Female283967
Male7253125
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PA21Sevelamer HydrochlorideTotal
American Indian or Alaska Native000
Asian10092192
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Dialysis vintage
Dialysis vintage(months)PA21Sevelamer HydrochlorideTotal
Mean104.9 ± 79.7102.4 ± 90.6103.7 ± 84.8
08

Study locations

1 site
  • Multiple Locations, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Dec 2013, 8 months.

Results were first posted in Oct 2018, 4 years 10 months after primary completion.

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2013
First posted
May 9, 2013
StartActual
Apr 23, 2013
Primary completionActual
Dec 2013
CompletionActual
Dec 10, 2013
Results first posted
Oct 9, 2018
Last update
Oct 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01850602
Responsible party
Sponsor
First posted
May 9, 2013
Start date
Apr 23, 2013
Primary completion
Dec 2013
Completion
Dec 10, 2013
Results posted
Oct 9, 2018
Last update
Oct 9, 2018
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA21

Start the discussion